Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis-Reference-Cited by-同舟云学术

Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis

Published:2022-04-21 Issue:4 Volume:5 Page:e228330
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Roberts Jordan E.¹,Fan Mary¹,Son Mary Beth F.¹

Affiliation:

1. Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2791440/roberts_2022_ld_220072_1649955302.29959.pdf

Reference6 articles.

1. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis.;Ringold;Arthritis Care Res (Hoboken),2019

2. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.;Mannion;J Rheumatol,2014

3. Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis.;Suarez-Almazor;J Rheumatol,2007

4. Impact of plan-level access restrictions on effectiveness of biologics among patients with rheumatoid or psoriatic arthritis.;Boytsov;Pharmacoecon Open,2020

5. Treatment delays associated with prior authorization for infusible medications: a cohort study.;Wallace;Arthritis Care Res (Hoboken),2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sociodemographic and Visual Outcomes of Juvenile Idiopathic Arthritis Uveitis: IRIS® Registry Study;Clinical Ophthalmology;2024-05

2. Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry;The Journal of Rheumatology;2022-12-15